[go: up one dir, main page]

MX2007014405A - Novedosos derivados de oxadiazol y su uso como moduladores aloestericos positivos de los receptores de glutamato metabotropicos. - Google Patents

Novedosos derivados de oxadiazol y su uso como moduladores aloestericos positivos de los receptores de glutamato metabotropicos.

Info

Publication number
MX2007014405A
MX2007014405A MX2007014405A MX2007014405A MX2007014405A MX 2007014405 A MX2007014405 A MX 2007014405A MX 2007014405 A MX2007014405 A MX 2007014405A MX 2007014405 A MX2007014405 A MX 2007014405A MX 2007014405 A MX2007014405 A MX 2007014405A
Authority
MX
Mexico
Prior art keywords
oxadiazole derivatives
metabotropic glutamate
positive allosteric
glutamate receptors
allosteric modulators
Prior art date
Application number
MX2007014405A
Other languages
English (en)
Inventor
Jean-Philippe Rocher
Stefania Gagliardi
Emmanuel Le Poul
Giovanni Palombi
Piergiuliano Bugada
Vincent Mutel
Original Assignee
Addex Pharmaceuticals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Addex Pharmaceuticals Sa filed Critical Addex Pharmaceuticals Sa
Publication of MX2007014405A publication Critical patent/MX2007014405A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La presente invencion se refiere a nuevos compuestos que son derivados de oxadiazol de la formula (I) (ver formula (I)): en donde B, P, Q, W, R1, y R2 se definen en la descripcion. Los compuestos de la invencion son utiles en la prevencion o el tratamiento de trastornos del sistema nervioso central o periferico, asi como de otros trastornos modulados por los receptores de mGluR5.
MX2007014405A 2005-05-18 2006-05-17 Novedosos derivados de oxadiazol y su uso como moduladores aloestericos positivos de los receptores de glutamato metabotropicos. MX2007014405A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0510142.3A GB0510142D0 (en) 2005-05-18 2005-05-18 Novel compounds A1
PCT/IB2006/001674 WO2006123249A2 (en) 2005-05-18 2006-05-17 Novel oxadiazole derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors

Publications (1)

Publication Number Publication Date
MX2007014405A true MX2007014405A (es) 2008-04-21

Family

ID=34708380

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007014405A MX2007014405A (es) 2005-05-18 2006-05-17 Novedosos derivados de oxadiazol y su uso como moduladores aloestericos positivos de los receptores de glutamato metabotropicos.

Country Status (17)

Country Link
US (1) US20090197897A1 (es)
EP (1) EP1896463A2 (es)
JP (1) JP2008540634A (es)
KR (1) KR20080031676A (es)
CN (1) CN101218232B (es)
AU (1) AU2006248649B2 (es)
BR (1) BRPI0610681A2 (es)
CA (1) CA2608012A1 (es)
EA (1) EA015263B1 (es)
GB (1) GB0510142D0 (es)
IL (1) IL187190A0 (es)
MX (1) MX2007014405A (es)
NO (1) NO20076479L (es)
NZ (1) NZ564253A (es)
UA (1) UA92496C2 (es)
WO (1) WO2006123249A2 (es)
ZA (1) ZA200710277B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0510141D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B3
NZ564254A (en) * 2005-05-18 2011-04-29 Addex Pharma Sa Substituted oxadiazole derivatives as positive allosteric modulators of metabotropic glutamate receptors
GB0510140D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B2
US7807706B2 (en) 2005-08-12 2010-10-05 Astrazeneca Ab Metabotropic glutamate-receptor-potentiating isoindolones
GB0622202D0 (en) * 2006-11-07 2006-12-20 Addex Pharmaceuticals Sa Novel compounds
TW200911255A (en) 2007-06-07 2009-03-16 Astrazeneca Ab Metabotropic glutamate receptor oxadiazole ligands and their use as potentiators-841
TWI417100B (zh) * 2007-06-07 2013-12-01 Astrazeneca Ab 二唑衍生物及其作為代謝型麩胺酸受體增效劑-８４２之用途
EA201070143A1 (ru) 2007-07-13 2010-08-30 Аддекс Фарма С.А. Новые гетероароматические производные и их использование в качестве положительных аллостерических модуляторов метаботропных глутаматных рецепторов
WO2009099177A1 (ja) * 2008-02-06 2009-08-13 Taisho Pharmaceutical Co., Ltd. アミノイミダゾール誘導体
SA109300358B1 (ar) 2008-06-06 2012-11-03 استرازينيكا ايه بي مقويات مستقبل جلوتامات ذي انتحاء أيضي من أيزو إندولون
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
US20100222381A1 (en) 2009-02-27 2010-09-02 Hariprasad Vankayalapati Cyclopentathiophene/cyclohexathiophene DNA methyltransferase inhibitors
WO2010124055A1 (en) * 2009-04-23 2010-10-28 Merck Sharp & Dohme Corp. 2-alkyl piperidine mglur5 receptor modulators
CA2784830C (en) 2009-12-18 2018-03-27 Sunovion Pharmaceuticals Inc. Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
EP2531510B1 (en) 2010-02-01 2014-07-23 Novartis AG Pyrazolo[5,1b]oxazole derivatives as crf-1 receptor antagonists
WO2011092293A2 (en) 2010-02-01 2011-08-04 Novartis Ag Cyclohexyl amide derivatives as crf receptor antagonists
US8835444B2 (en) 2010-02-02 2014-09-16 Novartis Ag Cyclohexyl amide derivatives as CRF receptor antagonists
EP2668951B9 (en) * 2011-01-25 2017-03-15 Viviabiotech, S.L. 1,2,4-oxadiazole derivatives as drugs modulating the glp-1 peptide receptor
KR101689093B1 (ko) 2012-06-04 2016-12-22 액테리온 파마슈티칼 리미티드 벤즈이미다졸-프롤린 유도체
JP6244365B2 (ja) 2012-10-10 2017-12-06 アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ ［オルトビ−（ヘテロ−）アリール］−［２−（メタビ−（ヘテロ−）アリール）−ピロリジン−１−イル］−メタノン誘導体であるオレキシン受容体アンタゴニスト
CN105051040A (zh) 2013-03-12 2015-11-11 埃科特莱茵药品有限公司 作为食欲素受体拮抗剂的氮杂环丁烷酰胺衍生物
MX366642B (es) 2013-12-04 2019-07-17 Idorsia Pharmaceuticals Ltd Uso de derivados de bencimidazol-prolina.
WO2016153023A1 (ja) * 2015-03-25 2016-09-29 国立研究開発法人国立長寿医療研究センター 新規オキサジアゾール誘導体及びこれを含有する医薬
EP3914592A1 (en) * 2019-01-25 2021-12-01 University of Virginia Patent Foundation Inhibitors of spinster homolog 2 (spns2) for use in therapy
US20230373937A1 (en) * 2020-09-09 2023-11-23 University Of Virginia Patent Foundation Inhibitors of spinster homolog 2 (spns2) for use in therapy
IL291418B2 (en) 2022-03-16 2024-05-01 Anima Biotech Inc Substances that function as modulators of cMYC-mRNA translation and their uses for cancer treatment

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK162087D0 (da) * 1987-03-31 1987-03-31 Ferrosan As Piperidinforbindelser, deres fremstilling og anvendelse
DE19643037A1 (de) * 1996-10-18 1998-04-23 Boehringer Ingelheim Kg Neue Oxadiazole, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel
US6107313A (en) * 1998-10-02 2000-08-22 Combichem, Inc. Dopamine receptor antagonists
AU769260B2 (en) * 1998-10-07 2004-01-22 Georgetown University Monomeric and dimeric heterocycles, and therapeutic uses thereof
AU5891600A (en) * 1999-07-01 2001-01-22 Chemrx Advanced Technologies, Inc. Process for synthesizing oxadiazoles
JP3790472B2 (ja) * 1999-08-19 2006-06-28 エヌピーエス ファーマシューティカルズ インコーポレーテッド ヘテロ多環式化合物および代謝型グルタミン酸受容体アンタゴニストとしてのその使用
WO2001054503A1 (en) * 2000-01-28 2001-08-02 Akkadix Corporation Methods for killing nematodes and nematode eggs using 4-phenoxy-6-aminopyrimidine derivatives
SI1379525T1 (sl) * 2001-02-21 2007-12-31 Astrazeneca Ab Heteropoliciklične spojine in njihova uporaba kot antagonisti metabotropnih glutamatnih receptorjev
GB0115862D0 (en) * 2001-06-28 2001-08-22 Smithkline Beecham Plc Compounds
CA2460121C (en) * 2001-09-21 2010-11-02 Mitsubishi Pharma Corporation 3-substituted-4-pyrimidone derivatives
MXPA04002661A (es) * 2001-09-21 2004-11-22 Sanofi Aventis Derivados de pirimidona 4, 3-sustituida.
US6995144B2 (en) * 2002-03-14 2006-02-07 Eisai Co., Ltd. Nitrogen containing heterocyclic compounds and medicines containing the same
US7074809B2 (en) * 2002-08-09 2006-07-11 Astrazeneca Ab Compounds
IL166510A0 (en) * 2002-08-09 2006-01-15 Nps Pharma Inc 1,2,4"oxadiazole as modulators of metabotropic glutamate receptor-5
AU2003274956A1 (en) 2002-09-06 2004-03-29 Janssen Pharmaceutica, N.V. Use of indolyl derivatives for the manufacture of a medicament for the treatment allergic rhinitis
GB2415430B (en) * 2003-03-12 2006-07-12 Kudos Pharm Ltd Phthalazinone derivatives
US7507836B2 (en) 2003-03-26 2009-03-24 Merck & Co. Inc. Benzamide modulators of metabotropic glutamate receptors
GB0325956D0 (en) * 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
NZ548693A (en) * 2004-02-18 2010-05-28 Astrazeneca Ab Polyheterocyclic compounds and their use as metabotropic glutamate receptor antagonists
EP2266969A3 (en) * 2004-09-29 2011-02-16 Mitsubishi Tanabe Pharma Corporation 6-(Pyridinyl)-4-pyrimidone derivatives as tau protein kinase 1 inhibitors
GB0510143D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds A1
GB0510141D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B3
GB0510139D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B1
NZ564254A (en) * 2005-05-18 2011-04-29 Addex Pharma Sa Substituted oxadiazole derivatives as positive allosteric modulators of metabotropic glutamate receptors
GB0510140D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B2
GB0622202D0 (en) * 2006-11-07 2006-12-20 Addex Pharmaceuticals Sa Novel compounds

Also Published As

Publication number Publication date
NO20076479L (no) 2008-01-29
UA92496C2 (ru) 2010-11-10
CN101218232A (zh) 2008-07-09
US20090197897A1 (en) 2009-08-06
JP2008540634A (ja) 2008-11-20
WO2006123249A2 (en) 2006-11-23
CA2608012A1 (en) 2006-11-23
WO2006123249A3 (en) 2007-02-08
CN101218232B (zh) 2012-06-27
ZA200710277B (en) 2009-03-25
EA015263B1 (ru) 2011-06-30
NZ564253A (en) 2011-04-29
AU2006248649B2 (en) 2012-04-26
GB0510142D0 (en) 2005-06-22
IL187190A0 (en) 2008-02-09
BRPI0610681A2 (pt) 2010-07-20
KR20080031676A (ko) 2008-04-10
EP1896463A2 (en) 2008-03-12
EA200702468A1 (ru) 2008-06-30
AU2006248649A1 (en) 2006-11-23

Similar Documents

Publication Publication Date Title
MX2007014405A (es) Novedosos derivados de oxadiazol y su uso como moduladores aloestericos positivos de los receptores de glutamato metabotropicos.
ZA200710279B (en) Pyrrole derivatives as positive allosteric modulators of metabotropic glutamate receptors
MXPA06014721A (es) Derivados de alquinilo como moduladores de los receptores de glutamato metabotropico.
UA83257C2 (en) Allosteric modulators of metabotropic glutamate receptors
MX2007014444A (es) Derivados de oxadiazol sustituido como moduladores aloestericos positivos de los receptores de glutamato metabotropicos.
DE602005025672D1 (de) Neuartige tetrazolderivate als positive allosterische modulatoren von metabotropen glutamatrezeptoren
MX2007014400A (es) Novedosos compuestos heterociclicos como moduladores aloestericos positivos de los receptores de glutamato metabotropicos.
WO2009010454A3 (en) Amido derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors
IL189298A0 (en) 3.5-disubstituted phenyl-piperidines as modulators of dopamine meurotransmission
ATE467632T1 (de) Pyrroloä2,3-büpyridinderivate als modulatoren des h3-rezeptors
HK1110076A (en) Novel oxadiazole derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors
HK1110852A (en) Substituted oxadiazole derivatives as positive allosteric modulators of metabotropic glutamate receptors
UA92495C2 (ru) Замещенные производные оксадиазола как положительные аллостерические модуляторы метаботропных глутаматных рецепторов
ATE479691T1 (de) 4,5,6,7-tetrahydrothienoä2,3-cüpyridine als h3- modulatoren
MY148488A (en) Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
MXPA06013945A (es) Piperidinas sustituidas, novedosas, como moduladores de la neurotransmision de dopamina.
HK1111148A (en) Novel heterocyclic compounds as positive allosteric modulators of metabotropic glutamate receptors
TW200602041A (en) Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists

Legal Events

Date Code Title Description
FA Abandonment or withdrawal